Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retlirafusp alfa + apatinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
Retlirafusp alfa + apatinib + nab-paclitaxel is a combination therapy being evaluated for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. Retlirafusp alfa (SHR-1701) is a bifunctional fusion protein that targets both programmed death-ligand 1 (PD-L1) and transforming growth factor-beta receptor II (TGF-βRII), aiming to reverse immune suppression in the tumor microenvironment. Apatinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), which inhibits tumor-induced angiogenesis. Nab-paclitaxel is an albumin-bound formulation of the cytotoxic agent paclitaxel, which disrupts microtubule function to inhibit cell division. This combination is specifically being studied as a second-line treatment for patients with HER2-negative advanced gastric or GEJ adenocarcinoma who have previously failed immunotherapy-containing regimens.
- Other names
- Retlirafusp alfa + Apatinib + Nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))TGFB (GARP–latent transforming growth factor beta 1 complex)CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on retlirafusp alfa + apatinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retlirafusp alfa + apatinib + nab-paclitaxel.